RARE - Company ID 0001515673
Ultragenyx Pharmaceutical Inc. (RARE) reported net income of -$575.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$575.00M | -1.1% |
| FY 2024 | -$569.00M | +6.3% |
| FY 2023 | -$607.00M | +14.2% |
| FY 2022 | -$707.42M | -55.8% |
| FY 2021 | -$454.02M | -143.4% |
| FY 2020 | -$186.57M | +53.7% |
| FY 2019 | -$402.73M | -103.8% |
| FY 2018 | -$197.61M | +34.6% |
| FY 2017 |
Ultragenyx Pharmaceutical Inc. (RARE) reported net income of -$575.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Ultragenyx Pharmaceutical Inc.'s net income declined from -$16.33M to -$575.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$302.14M |
| -22.9% |
| FY 2016 | -$245.87M | -68.8% |
| FY 2015 | -$145.62M | -143.5% |
| FY 2014 | -$59.80M | -70.5% |
| FY 2013 | -$35.07M | -114.7% |
| FY 2012 | -$16.33M | - |